Generating CRISPR/Cas9 Mediated Monoallelic Deletions to Study Enhancer Function in Mouse Embryonic Stem Cells
April 2nd, 2016
12.5K views
Experimental validation of enhancer activity is best approached by loss-of-function analysis. Presented here is an efficient protocol that uses CRISPR/Cas9 mediated deletion to study allele-specific regulation of gene transcription in F1 ES cells which contain a hybrid genome (Mus musculus129 x Mus castaneus).
Overview
This article presents a protocol for using CRISPR/Cas9 mediated deletion to study allele-specific regulation of gene transcription in mouse embryonic stem cells. The technique leverages a hybrid genome to facilitate the analysis of monoallelic deletions, providing insights into gene regulation.
Key Study Components
Area of Science
- Functional genomics
- Gene transcription regulation
- CRISPR/Cas9 technology
Background
- Understanding enhancer activity is crucial for gene regulation.
- Loss-of-function analysis is a key approach in this field.
- Mouse embryonic stem cells provide a model for studying gene regulation.
- Hybrid genomes can help in analyzing specific gene interactions.
Purpose of Study
- To investigate the role of specific enhancers in gene regulation.
- To determine the dependency of genes on particular enhancers.
- To enhance understanding of stem cell pluripotency and its applications.
Methods Used
- CRISPR/Cas9 mediated deletion technique.
- Use of F1 ES cells with a hybrid genome (Mus musculus 129 x Mus castaneus).
- Analysis of monoallelic deletions to study gene transcription.
- Experimental validation of enhancer activity through loss-of-function analysis.
Main Results
- Successful implementation of allele-specific deletions in stem cells.
- Insights into the regulation of gene transcription by specific enhancers.
- Demonstration of the method's applicability to various biological systems.
- Contribution to the understanding of functional genomics.
Conclusions
- The CRISPR/Cas9 method is effective for studying enhancer activity.
- This approach can clarify the relationship between enhancers and gene expression.
- Findings may have broader implications for stem cell research and functional genomics.
Frequently Asked Questions
What is the main advantage of using CRISPR/Cas9 in this study?
The main advantage is the ability to perform allele-specific deletions, allowing for precise analysis of gene regulation.
How does the hybrid genome contribute to the study?
The hybrid genome enables the generation of monoallelic deletions, facilitating the study of specific gene interactions.
What are the implications of this research?
This research provides insights into enhancer-gene relationships and can inform stem cell pluripotency studies.
Can this method be applied to other biological systems?
Yes, while focused on stem cells, the method can be adapted for use in various biological contexts.
What key questions does this study aim to answer?
It aims to determine which genes specific enhancers regulate and their dependency on those enhancers for activity.
What is the significance of loss-of-function analysis?
Loss-of-function analysis is crucial for understanding the role of enhancers in gene regulation.
Executive Industry Relevance
This protocol enables precise interrogation of enhancer function through allele-specific CRISPR/Cas9 deletion in hybrid mouse embryonic stem cells, addressing a key challenge in target validation: linking distal regulatory elements to gene expression. By leveraging natural SNPs between Mus musculus 129 and Mus castaneus alleles, the approach supports mechanistic de-risking of transcriptional regulators without confounding homozygous lethality, providing predictive confidence in enhancer-gene relationships early in discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables therapeutic hypothesis interrogation by testing enhancer necessity for gene expression in a physiologically relevant stem cell model.
- Scientific Value: Supports biological de-risking through monoallelic loss-of-function analysis that avoids phenotypic confounding from complete regulatory element deletion.
- Scientific Value: Enhances target confidence by providing direct cis-regulatory evidence via allele-specific deletion screening using SNP-discriminating primers.
Screening & Assay Development
- Operational Value: Facilitates assay standardization through qPCR-based genotyping with allele-specific inside and outside primers to distinguish heterozygous, homozygous, and wild-type clones.
- Operational Value: Enables scalable screening workflow using 96-well plate colony picking and qPCR on 384-well plates for high-throughput deletion validation.
- Operational Value: Supports assay reproducibility by requiring confirmation of no indels on the non-deleted allele via gRNA-flanking primers before expression analysis.
Translational & Preclinical Research
- Translational Value: Provides disease-relevant system insights by studying enhancer-mediated regulation of pluripotency factors like Sox2 in mouse embryonic stem cells.
- Translational Value: Supports predictive confidence in stem cell fate decisions by linking enhancer deletion to changes in gene expression relevant to differentiation pathways.
- Translational Value: Enables mechanistic de-risking of enhancer targets through quantitative expression analysis (qPCR) showing allele-specific reduction in target gene transcription.
Pipeline & Workflow Integration
The method fits within the discovery biology to lead identification continuum by providing functional validation of non-coding regulatory elements prior to therapeutic targeting, with outputs directly informing target prioritization and de-risking decisions.
- Discovery Biology: Supports hypothesis testing of enhancer-gene relationships through allele-specific deletion and expression analysis in a genetically tractable model.
- Screening: Delivers assay readiness via standardized qPCR workflow using allele-specific primers to quantify deletion efficiency and specificity across clones.
- Analytics: Provides quantitative dependent variable measurements (CT values, melt curves) that enable comparison of allelic expression and deletion zygosity.
- Translational Research: Connects to preclinical continuity by studying enhancer function in a stem cell model relevant to differentiation and disease modeling.
- Enterprise Reuse: Establishes a reusable capability for enhancer validation across genomic regions using the same SNP-based primer design and CRISPR workflow.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in enhancer function through direct loss-of-function evidence without compensatory mechanisms from homozygous deletion.
- Operational Value: Standardization and reproducibility via SNP-guided allele-specific primer design and qPCR screening protocols.
- Strategic Value: Better go/no-go decisions by clarifying enhancer dependency and reducing mechanistic ambiguity in target validation.
- Portfolio Impact: Risk-adjusted prioritization of transcriptional targets based on validated enhancer-gene relationships in a disease-relevant cellular context.
Implementation Considerations
- Requires expertise in CRISPR/Cas9 design, allele-specific primer engineering, and qPCR analysis for allelic discrimination.
- Dependent on access to F1 hybrid embryonic stem cells with sufficient SNP density (every ~125 bp) for reliable allele-specific targeting.
- Necessitates standardization across teams for primer design workflows using UCSC genome browser and Primer3Plus to ensure allele specificity.
- Involves adaptation considerations for non-hybrid models where SNP density may be insufficient for allele-specific resolution.
- Includes practical limitations such as the need to confirm absence of indels on the non-deleted allele before attributing expression changes to enhancer loss.
Biopharma FAQs
Why does allele-specific deletion avoid confounding phenotypes in target validation?
Monoallelic deletion preserves one functional allele, preventing lethality or severe phenotypic disruption that could obscure enhancer-specific effects on gene expression, enabling clearer interpretation of cis-regulatory function.
How does SNP density in hybrid ES cells enable precise genotyping of deletions?
Natural SNPs occurring every ~125 bp between Mus musculus 129 and Mus castaneus alleles allow design of allele-specific primers that discriminate amplification from each haplotype, facilitating accurate zygosity assessment.
What quantitative measurements confirm successful enhancer deletion and allelic specificity?
qPCR using allele-specific inside primers shows CT value differences >5 cycles or no amplification for the deleted allele, while outside primers confirm deletion size; melt curve analysis validates product specificity.
Why is confirmation of no indels on the non-deleted allele required before expression analysis?
Indels on the wild-type allele could alter gene expression independently, confounding results; gRNA-flanking primers ensure observed expression changes are due solely to enhancer deletion.
What statistical thresholds support go/no-go decisions in enhancer target validation?
CT value differences >5 cycles between alleles indicate heterozygous deletion; consistent allelic expression reduction (e.g., Sox2) across multiple monoallelic clones supports dependency and informs advancement decisions.
